Sage Therapeutics depression drug disappoints

New data from trial involving a drug treating severe depression disappoints the stock market, and biotech company Sage Therapeutics faces share price decline.


Sage Therapeutics took an 18.8 percent dive to USD 59.15 in the US pre-market after the US biotech firm generated disappointing results from a trial involving a potential treatment for severe depression.

Bloomberg News highlights that this late-stage trial, completed in collaboration with Biogen, reached its primary endpoint with improved depression symptoms, whereas the long-term effect was one of the major concerns ahead of the trial results being published.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs